Abu Dhabi AI-powered healthcare firm M42 is mapping the genetic makeup of Emiratis through the Emirati Genome Project. The initiative has sequenced over 802,000 genomes and nearly three-quarters of the local Emirati population, building one of the world's most comprehensive genetic databases. With the majority of global genetic databases focused on European ancestry, the Emirati Genome Project helps researchers address health problems prevalent in the UAE, anticipate risks for inherited medical conditions and create more personalized healthcare experiences for Middle Eastern populations.

Why This Matters

M42's population-scale genetic database offers researchers a rare opportunity to accelerate medical research and drug discovery. As M42 works to commercialize access to this genetic data, the close UAE-US healthcare partnership is creating opportunities for American biotech companies, pharmaceutical firms and research institutions to collaborate on breakthrough medical research. US companies can leverage the database to develop more effective treatments while advancing precision medicine that accounts for genetic diversity.

For more on how the UAE–US economic partnership is accelerating through backing US innovators, scaling businesses, and creating jobs, sign up for our bi-weekly newsletter.

Related

View All

Health Technology

Abu Dhabi's M42 Sequences 800,000+ Genomes to Fuel Medical Research

April 2025

0

min read

Genome sequencing equipment at M42's genomic research facility in Abu Dhabi, supporting the Emirati Genome Project.

M42 genome sequencing facility in Abu Dhabi

Abu Dhabi AI-powered healthcare firm M42 is mapping the genetic makeup of Emiratis through the Emirati Genome Project. The initiative has sequenced over 802,000 genomes and nearly three-quarters of the local Emirati population, building one of the world's most comprehensive genetic databases. With the majority of global genetic databases focused on European ancestry, the Emirati Genome Project helps researchers address health problems prevalent in the UAE, anticipate risks for inherited medical conditions and create more personalized healthcare experiences for Middle Eastern populations.

Why This Matters

M42's population-scale genetic database offers researchers a rare opportunity to accelerate medical research and drug discovery. As M42 works to commercialize access to this genetic data, the close UAE-US healthcare partnership is creating opportunities for American biotech companies, pharmaceutical firms and research institutions to collaborate on breakthrough medical research. US companies can leverage the database to develop more effective treatments while advancing precision medicine that accounts for genetic diversity.

For more on how the UAE–US economic partnership is accelerating through backing US innovators, scaling businesses, and creating jobs, sign up for our bi-weekly newsletter.